BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock Forecast
BBOT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 12 analysts
- Price target
- $24.55 average of analyst targets
- Upside to target
- +770.4% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.65
- 52-week range
- $2.82 – $13.73
BBOT analyst ratings
12 analystsNumber of analysts at each rating.
BBOT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BBOT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.66 | −$0.80 | −$0.49 | −$1.03 | +36.0% | 10 |
| Current fiscal year (2026) | −$2.85 | −$4.61 | −$1.98 | −$4.30 | +33.8% | 11 |
| Next fiscal year (2027) | −$2.72 | −$5.52 | −$1.86 | −$2.85 | +4.5% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BBOT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 9 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 9 |
BBOT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BBOT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.56 | −$0.66 | −$0.66 | −$0.66 | +17.1% | 1 up · 7 down |
| Current fiscal year (2026) | −$2.23 | −$2.21 | −$2.68 | −$2.85 | −$2.85 | +27.5% | 0 up · 9 down |
| Next fiscal year (2027) | −$2.12 | −$2.11 | −$2.41 | −$2.72 | −$2.72 | +27.8% | 2 up · 6 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BBOT earnings surprises
Reported EPS vs the consensus estimate for the last 10 quarters; BBOT beat in 1 of 4.
What analysts expect from BBOT
12 analysts cover BridgeBio Oncology Therapeutics; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $24.55, 770.4% above the latest close of $2.82. Analysts expect earnings of −$2.85 per share for 2026, +33.8% from a year earlier. For 2027 the average estimate is −$2.72 per share. BridgeBio Oncology Therapeutics beat the EPS estimate in 1 of the last 4 quarters.
Related: BBOT income statement, BBOT key metrics, BBOT chart. See the BBOT stock overview for the latest quote and news.
BBOT forecast FAQ
What is BridgeBio Oncology Therapeutics's price target?
The average analyst price target for BridgeBio Oncology Therapeutics is $24.55, 770.4% above the latest close of $2.82.
Is BridgeBio Oncology Therapeutics a buy, hold or sell?
Of 12 analysts covering BridgeBio Oncology Therapeutics, 8 rate it a strong buy, 4 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is BridgeBio Oncology Therapeutics's EPS forecast?
Analysts forecast −$2.85 per share for 2026 (range −$4.61 to −$1.98); for 2027 the estimate is −$2.72.
When does BridgeBio Oncology Therapeutics report earnings?
BridgeBio Oncology Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes; the EPS estimate is $-0.65.
Does BridgeBio Oncology Therapeutics usually beat earnings estimates?
BridgeBio Oncology Therapeutics reported EPS at or above the analyst estimate in 1 of the last 4 quarters.